Unbuzzd Trial Confirms Accelerated Alcohol Metabolism
On March 23, 2026, Quantum BioPharma announced the publication of a peer-reviewed clinical trial for its Unbuzzd formula, a product designed to counter the effects of alcohol. The study's results demonstrated that Unbuzzd significantly accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration (BAC), and mitigates symptoms of intoxication and hangovers. The successful trial provides scientific validation for the product, opening a path toward a substantial consumer wellness and safety market for which there are few competitors.
Company Secures C$3.75M in Financing
Just three days prior to the trial announcement, on March 20, 2026, Quantum BioPharma closed the initial tranche of a private placement, securing C$3.75 million in gross proceeds. The capital was raised for ongoing business development and general working capital, providing the company with fresh resources as it supports the commercialization of Unbuzzd. Notably, a company director participated in the offering, subscribing for C$300,000 worth of debenture units, signaling strong insider confidence in the company's strategy and prospects.
Royalty Structure Defines Financial Upside from Unbuzzd
Quantum BioPharma's financial benefit from Unbuzzd is defined by a clear and potentially lucrative business structure. The company invented the product and spun out the over-the-counter (OTC) version to Celly Nutrition Corp. In the deal, Quantum BioPharma retained a 25.71% ownership stake in Celly Nutrition. Furthermore, it secured a 7% royalty on all Unbuzzd sales until total payments reach $250 million, at which point the royalty converts to 3% in perpetuity. This arrangement provides both immediate revenue potential and long-term value from its equity position, supplemented by a large tax loss carry-forward asset of approximately C$130 million.
